Satellos Bioscience (NASDAQ:MSLE) Releases Earnings Results, Misses Estimates By $0.18 EPS

Satellos Bioscience (NASDAQ:MSLE) announced its earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.18), Zacks reports.

Satellos Bioscience Stock Performance

NASDAQ:MSLE traded down $0.20 during trading on Thursday, reaching $9.82. The company’s stock had a trading volume of 46,664 shares, compared to its average volume of 49,999. Satellos Bioscience has a 12 month low of $4.84 and a 12 month high of $13.39. The company has a market capitalization of $204.65 million, a price-to-earnings ratio of -6.14 and a beta of 1.51. The company has a 50 day simple moving average of $8.13.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on MSLE shares. HC Wainwright raised their price objective on Satellos Bioscience from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Canaccord Genuity Group upgraded shares of Satellos Bioscience to a “moderate buy” rating in a research note on Thursday, May 21st. Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Wells Fargo & Company set a $18.00 price target on shares of Satellos Bioscience in a report on Thursday, July 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Friday, August 7th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Satellos Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $19.75.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.